PBSV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBSV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pharma-Bio Serv's basic earnings per share (Basic EPS) for the three months ended in Jan. 2024 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2024 was $0.03.
Pharma-Bio Serv's EPS (Diluted) for the three months ended in Jan. 2024 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $0.03.
Pharma-Bio Serv's EPS without NRI for the three months ended in Jan. 2024 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2024 was 0.03.
During the past 12 months, Pharma-Bio Serv's average EPS without NRIGrowth Rate was -46.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Pharma-Bio Serv's highest 3-Year average EPS without NRI Growth Rate was 130.10% per year. The lowest was -43.10% per year. And the median was -16.05% per year.
The historical data trend for Pharma-Bio Serv's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv Annual Data | |||||||||||||||||||||
Trend | Oct14 | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | 0.09 | 0.09 | -0.09 | 0.04 | 0.06 |
Pharma-Bio Serv Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
EPS (Basic) | Get a 7-Day Free Trial | 0.02 | 0.02 | 0.02 | - | -0.01 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Pharma-Bio Serv's Basic EPS for the fiscal year that ended in Oct. 2023 is calculated as
Basic EPS (A: Oct. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (1.31 | - | 0) | / | 22.971 | |
= | 0.06 |
Pharma-Bio Serv's Basic EPS for the quarter that ended in Jan. 2024 is calculated as
Basic EPS (Q: Jan. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-0.271 | - | 0) | / | 22.962 | |
= | -0.01 |
EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (OTCPK:PBSV) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Pharma-Bio Serv's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Elizabeth Plaza | 10 percent owner | 363 DORADO BEACH EAST, DORADO PR 00646 |
Altura Victor Sanchez | officer: President and CEO | C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646 |
San Juan Holdings | 10 percent owner | 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917 |
Pedro J Lasanta | officer: Chief Financial Officer | 373 MENDEZ VIGO, STE 110, DORADO PR 00646 |
Dov Perlysky | director | 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559 |
L P Venturetek | 10 percent owner | C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017 |
Barron Partners Lp | 10 percent owner | 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019 |
Manuel O Morera | officer: Chief Financial Officer | 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646 |
Mark A Fazio | officer: Exec. Vice President and COO | P O BOX 1026 GREEN STREET, PERKASIE PA 18944 |
Kirk Wheeler Michel | director | 209 EAST TRYON STREET, HILLSBOROUGH NC 27278 |
Irving L Wiesen | director | 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804 |
Howard Spindel | director | 39 BROADWAY SUITE 3300, NEW YORK NY 10028 |
Nelida Plaza Rodriguez | officer: Vice President and Secretary | G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646 |
Krovim Llc | director, 10 percent owner, officer: Manager | P.O. BOX 339, LAWRENCE NY 11559 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 02-12-2022
By ACCESSWIRE ACCESSWIRE • 02-01-2021
By ACCESSWIRE ACCESSWIRE • 03-18-2023
By ACCESSWIRE ACCESSWIRE • 09-15-2020
By [email protected] [email protected] • 09-16-2019
By ACCESSWIRE AccessWire • 04-12-2019
By ACCESSWIRE ACCESSWIRE • 03-18-2022
By [email protected] [email protected] • 06-16-2020
By ACCESSWIRE AccessWire • 04-12-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.